

## **Galmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016**

TEL AVIV, Israel, July 27, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Wednesday, August 3<sup>rd</sup>, 2016 to discuss results for the period ended June 30, 2016 and to provide an update on current developments with respect to its clinical programs for Aramchol™.

### ***Conference Call & Webcast***

**Wednesday, August 3<sup>rd</sup>, 2016, 8:30 am Eastern Time / 5:30 am Pacific Time**

Participant Dial-In Numbers:

Toll-Free: +1-888-364-3108

Toll/International: +1-719-457-2697

Conference ID: 3984671

Webcast: <http://galmedpharma.investorroom.com/events>

**Replay, available until August 17<sup>th</sup>, 2016**

Replay Dial-In Numbers:

Toll-Free: +1-877-870-5176

Toll/International: +1-858-384-5517

Passcode: 3984671

### **About Galmed Pharmaceuticals Ltd.:**

Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02279524) identifier: NCT02279524.

### **Forward-Looking Statements:**

*This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends,"*

*"plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include risks and uncertainties associated with the timing, progress and results of the Company's research, preclinical studies and clinical trials as well as risks and uncertainties identified under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, or the SEC, on March 22, 2016, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

Logo - <http://photos.prnewswire.com/prnh/20150720/238362LOGO>

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Investor Contact: Josh Blacher, CFO, Galmed Pharmaceuticals Ltd.,  
[josh@galmedpharma.com](mailto:josh@galmedpharma.com), +1-646-780-7605

---

Additional assets available online: [Photos \(1\)](#)

<https://galmedpharma.investorroom.com/2016-07-27-Galmed-Pharmaceuticals-Second-Quarter-2016-Conference-Call-and-Webcast-Scheduled-for-Wednesday-August-3rd-2016>